7157 related articles for article (PubMed ID: 2752501)
1. Activity of the pyrazoloacridines against multidrug-resistant tumor cells.
Sebolt J; Havlick M; Hamelehle K; Nelson J; Leopold W; Jackson R
Cancer Chemother Pharmacol; 1989; 24(4):219-24. PubMed ID: 2752501
[TBL] [Abstract][Full Text] [Related]
2. Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro.
Sebolt JS; Scavone SV; Pinter CD; Hamelehle KL; Von Hoff DD; Jackson RC
Cancer Res; 1987 Aug; 47(16):4299-304. PubMed ID: 2440564
[TBL] [Abstract][Full Text] [Related]
3. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
4. Comparative molecular field analysis of in vitro growth inhibition of L1210 and HCT-8 cells by some pyrazoloacridines.
Horwitz JP; Massova I; Wiese TE; Wozniak AJ; Corbett TH; Sebolt-Leopold JS; Capps DB; Leopold WR
J Med Chem; 1993 Nov; 36(23):3511-6. PubMed ID: 8280289
[TBL] [Abstract][Full Text] [Related]
5. Modulation of in vitro chemosensitivity by extracellular Ca++ in adriamycin sensitive and resistant P388 leukemic cells.
Adwankar MK; Chitnis MP
Neoplasma; 1990; 37(1):31-6. PubMed ID: 2320178
[TBL] [Abstract][Full Text] [Related]
6. A study of the mechanism of resistance to Adriamycin in vivo. Glutathione metabolism, P-glycoprotein expression, and drug transport.
Lee FY; Sciandra J; Siemann DW
Biochem Pharmacol; 1989 Nov; 38(21):3697-705. PubMed ID: 2574574
[TBL] [Abstract][Full Text] [Related]
7. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Goldenberg GJ; Wang H; Blair GW
Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
[TBL] [Abstract][Full Text] [Related]
8. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
[TBL] [Abstract][Full Text] [Related]
9. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors.
Leopold WR; Nelson JM; Plowman J; Jackson RC
Cancer Res; 1985 Nov; 45(11 Pt 1):5532-9. PubMed ID: 4053027
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of quinidine effect on the antitumor activity of adriamycin and mitoxantrone in adriamycin-sensitive and -resistant P388 leukemia cells.
Parekh H; Chitnis M
Sel Cancer Ther; 1990; 6(2):93-102. PubMed ID: 2367755
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine and phenylalanine restriction sensitizes adriamycin-resistant P388 leukemia cells to adriamycin.
Elstad CA; Thrall BD; Raha G; Meadows GG
Nutr Cancer; 1996; 25(1):47-60. PubMed ID: 8837861
[TBL] [Abstract][Full Text] [Related]
12. Effect of homoharringtonine on the viability of murine leukemia P388 cells resistant to either adriamycin, vincristine, or 1-beta-D-arabinofuranosylcytosine.
Wilkoff LJ; Dulmadge DA; Laster WR; Griswold DP
Cancer Chemother Pharmacol; 1989; 23(3):145-50. PubMed ID: 2924372
[TBL] [Abstract][Full Text] [Related]
13. The cytotoxicity of T-2 toxin and related 12,13-epoxytrichothecenes to Adriamycin-sensitive and -resistant P388 leukemia cells.
Ramu A; Yagen B; Ramu N
Cancer Chemother Pharmacol; 1989; 24(4):264-7. PubMed ID: 2752509
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein expression and modulation of cell-membrane morphology in adriamycin-resistant P388 leukemia cells.
Radel S; Fredericks W; Mayhew E; Baker R
Cancer Chemother Pharmacol; 1990; 25(4):241-6. PubMed ID: 1967228
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.
Waud WR; Plowman J; Harrison SD; Dykes DJ; Anderson WK; Griswold DP
Cancer Chemother Pharmacol; 1992; 30(4):261-6. PubMed ID: 1322803
[TBL] [Abstract][Full Text] [Related]
16. Potential antitumor agents. 52. Carbamate analogues of amsacrine with in vivo activity against multidrug-resistant P388 leukemia.
Rewcastle GW; Baguley BC; Atwell GJ; Denny WA
J Med Chem; 1987 Sep; 30(9):1576-81. PubMed ID: 3625706
[TBL] [Abstract][Full Text] [Related]
17. A benzophenazine derivative, N-beta-dimethylaminoethyl 9-carboxy-5-hydroxy-10-methoxy-benzo[a]phenazine-6-carboxamide, as a new antitumor agent against multidrug-resistant and sensitive tumors.
Tsuruo T; Naito M; Takamori R; Tsukahara S; Yamabe-Mitsuhashi J; Yamazaki A; Oh-hara T; Sudo Y; Nakaike S; Yamagishi T
Cancer Chemother Pharmacol; 1990; 26(2):83-7. PubMed ID: 2161296
[TBL] [Abstract][Full Text] [Related]
18. Carcinogenesis and aging. VIII. Effect of host age on tumour growth, metastatic potential, and chemotherapeutic sensitivity to 1.4-benzoquinone-guanylhydrazonethiosemicarbazone (ambazone) and 5-fluorouracil in mice and rats.
Baumgart J; Zhukovskaya NV; Anisimov VN
Exp Pathol; 1988; 33(4):239-48. PubMed ID: 3229459
[TBL] [Abstract][Full Text] [Related]
19. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
Johnson RK; Chitnis MP; Embrey WM; Gregory EB
Cancer Treat Rep; 1978 Oct; 62(10):1535-47. PubMed ID: 709555
[TBL] [Abstract][Full Text] [Related]
20. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists.
Klohs WD; Steinkampf RW; Havlick MJ; Jackson RC
Cancer Res; 1986 Sep; 46(9):4352-6. PubMed ID: 3460695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
